mRNA-1345在蛋白亚单位RSV疫苗基础免疫后≥12个月复种的安全性与免疫原性
该正在进行的3期开放标签试验评估≥60岁成人完成已上市蛋白亚单位RSV疫苗基础免疫≥12个月后复种mRNA-1345的安全性和免疫原性,共入组507人。复种耐受良好,未发现安全性问题;第29天RSV-A和RSV-B中和抗体几何平均滴度显著升高。事后比较显示异源复种后第29天滴度与关键效力研究中mRNA-1345基础免疫后滴度相当。
要点
- ≥60岁成人蛋白亚单位RSV疫苗基础免疫≥12个月后复种mRNA-1345耐受良好。
- 复种后第29天RSV-A和RSV-B中和抗体几何平均滴度显著升高。
- 异源复种后抗体水平与mRNA-1345基础免疫后相当。
核心结论
- ≥60岁成人完成已上市蛋白亚单位RSV疫苗基础免疫≥12个月后复种mRNA-1345具有良好耐受性,并能诱导RSV-A和RSV-B中和抗体滴度显著升高。
研究设计与样本
- 正在进行的3期开放标签试验,评估≥60岁成人完成已上市蛋白亚单位RSV疫苗基础免疫≥12个月后复种mRNA-1345,共入组507人,主要目标为安全性和免疫原性。
主要发现
- 复种耐受良好,未发现安全性问题。
- 第29天观察到RSV-A和RSV-B中和抗体几何平均滴度显著升高。
- 事后比较中,异源复种后第29天RSV-A和RSV-B的几何平均比分别为0.952(95%CI,0.847-1.070)和1.087(95%CI,0.964-1.226)。
临床怎么用
- 对于已完成已上市蛋白亚单位RSV疫苗基础免疫≥12个月的≥60岁成人,可考虑复种mRNA-1345以维持保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Protection from a single RSV vaccine dose is not lifelong, and revaccination may be needed to maintain it. This ongoing, phase 3, open-label trial evaluated revaccination with the RSV vaccine mRNA-1345 ≥12 months after primary vaccination with licensed protein subunit RSV vaccine in adults aged ≥60 years. Primary objectives were safety and immunogenicity. A total of 507 participants were enrolled. Revaccination was well-tolerated, with no safety concerns identified. Robust increases in RSV-A and RSV-B neutralizing antibody geometric mean titers were observed at Day 29. In a post hoc comparison of Day 29 titers following heterologous revaccination with those following primary mRNA-1345 vaccination in a subset of the pivotal efficacy study, geometric mean ratios for RSV-A and RSV-B were 0.952 (95% CI, 0.847-1.070) and 1.087 (95% CI, 0.964-1.226), respectively. These findings support revaccination with mRNA-1345 administered ≥12 months after primary vaccination with a licensed RSV protein subunit vaccine. TRIAL REGISTRATION: NCT07117487.
引用
- Desai M, Cardona J, Khetan S, et al. Safety and immunogenicity of mRNA-1345 revaccination at least 12 months following primary vaccination with a licensed protein subunit RSV vaccine. Vaccine. 2026. PMID: 42710149. doi:10.1016/j.vaccine.2026.129068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。